Rapport Therapeutics

Rapport Therapeutics appoints biotech leaders to Board, RAP-219 trials ongoing, topline data expected in Q1 2025, Phase 2a trial for focal epilepsy on track, IND for diabetic peripheral neuropathic pain on hold, $320.7 million in cash to fund operations through 2026.

Alto Neuroscience's ALTO-100 drug showed no significant improvement over placebo in a major depressive disorder trial, causing a sharp drop in share value. The company plans to analyze data to determine future steps for the drug, which is also being tested for PTSD and bipolar depression. Despite the setback, analysts believe Alto's biomarker-based approach remains promising.

Cooley sponsors Fierce Biotech Summit, focusing on biotech IPO outlook, cell therapy, and corporate affairs. A panel, including Cooley's Div Gupta, discusses the resurgence of biotech IPOs in 2024, comparing it to 2020's SPAC boom, and predicts future trends.

Recent advancements in neurology include positive phase 1/2 study results for tividenofusp alfa in Hunter syndrome, Delphi-MD for nerve stimulation, VG-3927 for Alzheimer's, and tirzepatide for sleep apnea. Ongoing trials for PGN-EDO51, tolebrutinib, and NS-050/NCNP-03 show promise. FDA discussions for CNM-Au8 and AMT-130, and approvals for Nerivio and STS101 highlight progress in treatment options.